1
|
Janowczyk A, Zlobec I, Walker C, Berezowska S, Huschauer V, Tinguely M, Kupferschmid J, Mallet T, Merkler D, Kreutzfeldt M, Gasic R, Rau TT, Mazzucchelli L, Eyberg I, Cathomas G, Mertz KD, Koelzer VH, Soldini D, Jochum W, Rössle M, Henkel M, Grobholz R. Swiss digital pathology recommendations: results from a Delphi process conducted by the Swiss Digital Pathology Consortium of the Swiss Society of Pathology. Virchows Arch 2023:10.1007/s00428-023-03712-5. [PMID: 38112792 DOI: 10.1007/s00428-023-03712-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 10/23/2023] [Accepted: 11/04/2023] [Indexed: 12/21/2023]
Abstract
Integration of digital pathology (DP) into clinical diagnostic workflows is increasingly receiving attention as new hardware and software become available. To facilitate the adoption of DP, the Swiss Digital Pathology Consortium (SDiPath) organized a Delphi process to produce a series of recommendations for DP integration within Swiss clinical environments. This process saw the creation of 4 working groups, focusing on the various components of a DP system (1) scanners, quality assurance and validation of scans, (2) integration of Whole Slide Image (WSI)-scanners and DP systems into the Pathology Laboratory Information System, (3) digital workflow-compliance with general quality guidelines, and (4) image analysis (IA)/artificial intelligence (AI), with topic experts for each recruited for discussion and statement generation. The work product of the Delphi process is 83 consensus statements presented here, forming the basis for "SDiPath Recommendations for Digital Pathology". They represent an up-to-date resource for national and international hospitals, researchers, device manufacturers, algorithm developers, and all supporting fields, with the intent of providing expectations and best practices to help ensure safe and efficient DP usage.
Collapse
Affiliation(s)
- Andrew Janowczyk
- Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, USA.
- Department of Oncology, Division of Precision Oncology, Geneva University Hospitals, Geneva, Switzerland.
- Department of Diagnostics, Division of Clinical Pathology, Geneva University Hospitals, Geneva, Switzerland.
| | - Inti Zlobec
- Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
| | - Cedric Walker
- Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| | - Sabina Berezowska
- Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | | | - Marianne Tinguely
- Institute of Pathology Enge, Zurich, Switzerland
- Medical Faculty, University of Zürich, Zurich, Switzerland
| | | | - Thomas Mallet
- Division of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland
| | - Doron Merkler
- Division of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland
- Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
| | - Mario Kreutzfeldt
- Division of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland
- Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
| | | | - Tilman T Rau
- Institute of Pathology, University Hospital and Heinrich-Heine University, Düsseldorf, Germany
- Institute of Pathology, University of Bern, Bern, Switzerland
| | | | - Isgard Eyberg
- Institute of Pathology, Cantonal Hospital Aarau, Aarau, Switzerland
| | - Gieri Cathomas
- Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
| | - Kirsten D Mertz
- Institute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland
| | - Viktor H Koelzer
- Department of Pathology and Molecular Pathology, University and University Hospital of Zürich, Zurich, Switzerland
| | | | - Wolfram Jochum
- Institute of Pathology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Matthias Rössle
- Pathologie Luzerner Kantonsspital (Pathology Cantonal Hospital Lucerne), Spitalstrasse, Switzerland
| | - Maurice Henkel
- Research & Analytic Services University Hospital Basel, Basel, Switzerland
- Institute of Radiology, University Hospital Basel, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | - Rainer Grobholz
- Medical Faculty, University of Zürich, Zurich, Switzerland
- Institute of Pathology, Cantonal Hospital Aarau, Aarau, Switzerland
| |
Collapse
|
2
|
Güth U, Elfgen C, Zadeh SN, Meier S, Varga Z, Tinguely M, Papassotiropoulos B, Däster K, Tausch CJ. The impact of intraoperative frozen section in patients with clinically node-negative breast cancer (cN0/ycN0) who received neoadjuvant systemic therapy. Eur J Surg Oncol 2023; 49:1423-1428. [PMID: 37183046 DOI: 10.1016/j.ejso.2023.04.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 04/18/2023] [Accepted: 04/24/2023] [Indexed: 05/16/2023]
Abstract
BACKGROUND When surgical axillary staging reveals residual metastatic deposits in breast cancer (BC) patients who had received neoadjuvant chemotherapy (NACT), axillary lymphonodectomy is indicated. In this study, we investigate whether it is reasonable to perform intraoperative frozen section (FS) of the removed sentinel lymph nodes (SLNs) in cases where NACT had been administered in patients who had a clinically negative nodal status at the time of diagnosis. PATIENTS AND METHODS We analyzed data from 101 BCE patients with 103 carcinomas who were diagnosed between 2014 and 2021 and met the above-mentioned criteria. RESULTS In three cases (2.8% of the study group), histologically active tumor tissue was detected in the removed axillary LNs. Discontinuation of therapy/the use of a low-dose NACT regimen was a significant factor for positive LNs (p = 0.02) at the subsequent surgical procedure; tumor progression during therapy approached borderline significance (p = 0.058). Among patients who had completed NACT with the planned standard dose regimen, and in which the primary tumors showed a response to therapy (n = 94), only one case had histologically detected residual metastases in the SLNs. CONCLUSIONS Certified breast centers aim to improve the outcome of the patients. However, these specialized centers should also focus on economic aspects. This means that diagnostic and therapeutic procedures should be continuously critically reviewed in order to avoid unnecessary expenses. In BC patients with clinically node negative disease who completed NACT as planned and in which the tumor showed a good response to therapy, time consuming and costly FS of the SLNs removed should be omitted.
Collapse
Affiliation(s)
- Uwe Güth
- Brust-Zentrum Zürich, Department of Breast Surgery, Seefeldstrasse 214, CH-8008, Zurich, Switzerland; University of Basel, Faculty of Medicine, Klingelbergstrasse 61, CH-4056, Basel, Switzerland.
| | - Constanze Elfgen
- Brust-Zentrum Zürich, Department of Breast Surgery, Seefeldstrasse 214, CH-8008, Zurich, Switzerland; University of Witten/Herdecke, Faculty of Medicine, Alfred-Herrhausen-Strasse 50, 58448, Witten, Germany
| | - Shadi Najaf Zadeh
- Brust-Zentrum Zürich, Department of Breast Surgery, Seefeldstrasse 214, CH-8008, Zurich, Switzerland
| | - Simon Meier
- Brust-Zentrum Zürich, Department of Breast Surgery, Seefeldstrasse 214, CH-8008, Zurich, Switzerland
| | - Zsuzsanna Varga
- Institute of Pathology and Molecular Pathology, University Hospital of Zurich, Schmelzbergstrasse 12, CH-8091, Zurich, Switzerland
| | - Marianne Tinguely
- Institute of Pathology Enge, Hardturmstrasse 133, CH-8055, Zurich, Switzerland; University of Zurich, Medical Faculty, Pestalozzistrasse 3, CH-8032, Zurich, Switzerland
| | - Bärbel Papassotiropoulos
- Brust-Zentrum Zürich, Department of Breast Surgery, Seefeldstrasse 214, CH-8008, Zurich, Switzerland
| | - Kavitha Däster
- Brust-Zentrum Zürich, Department of Breast Surgery, Seefeldstrasse 214, CH-8008, Zurich, Switzerland
| | - Christoph J Tausch
- Brust-Zentrum Zürich, Department of Breast Surgery, Seefeldstrasse 214, CH-8008, Zurich, Switzerland; University of Basel, Faculty of Medicine, Klingelbergstrasse 61, CH-4056, Basel, Switzerland
| |
Collapse
|
3
|
Palm C, Connolly CE, Masser R, Padberg Sgier B, Karamitopoulou E, Simon Q, Bode B, Tinguely M. Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors. Diagnostics (Basel) 2023; 13:diagnostics13010168. [PMID: 36611460 PMCID: PMC9818571 DOI: 10.3390/diagnostics13010168] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2022] [Revised: 12/21/2022] [Accepted: 12/24/2022] [Indexed: 01/05/2023] Open
Abstract
The expression of human epidermal growth factor receptor 2 (HER2) protein or gene transcripts is critical for therapeutic decision making in breast cancer. We examined the performance of a digitalized and artificial intelligence (AI)-assisted workflow for HER2 status determination in accordance with the American Society of Clinical Oncology (ASCO)/College of Pathologists (CAP) guidelines. Our preliminary cohort consisted of 495 primary breast carcinomas, and our study cohort included 67 primary breast carcinomas and 30 metastatic deposits, which were evaluated for HER2 status by immunohistochemistry (IHC) and in situ hybridization (ISH). Three practicing breast pathologists independently assessed and scored slides, building the ground truth. Following a washout period, pathologists were provided with the results of the AI digital image analysis (DIA) and asked to reassess the slides. Both rounds of assessment from the pathologists were compared to the AI results and ground truth for each slide. We observed an overall HER2 positivity rate of 15% in our study cohort. Moderate agreement (Cohen's κ 0.59) was observed between the ground truth and AI on IHC, with most discrepancies occurring between 0 and 1+ scores. Inter-observer agreement amongst pathologists was substantial (Fleiss´ κ 0.77) and pathologists' agreement with AI scores was 80.6%. Substantial agreement of the AI with the ground truth (Cohen´s κ 0.80) was detected on ISH-stained slides, and the accuracy of AI was similar for the primary and metastatic tumors. We demonstrated the feasibility of a combined HER2 IHC and ISH AI workflow, with a Cohen's κ of 0.94 when assessed in accordance with the ASCO/CAP recommendations.
Collapse
Affiliation(s)
- Christiane Palm
- Pathologie Institute Enge, 8005 Zurich, Switzerland
- Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland
| | | | | | | | | | | | - Beata Bode
- Pathologie Institute Enge, 8005 Zurich, Switzerland
- Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland
| | - Marianne Tinguely
- Pathologie Institute Enge, 8005 Zurich, Switzerland
- Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland
| |
Collapse
|
4
|
Asper N, Roth KS, Hany TF, Salzberg SP, Tinguely M, Kadvany Y, Trojan A. Metastatic Salivary Duct Carcinoma with ERBB2 Amplification and Sequential Response to Ado-Trastuzumab Emtansine and Neratinib: A Case Report. Case Rep Oncol 2023; 16:1500-1507. [PMID: 38033416 PMCID: PMC10686627 DOI: 10.1159/000535097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Accepted: 11/06/2023] [Indexed: 12/02/2023] Open
Abstract
Introduction Salivary duct carcinoma (SDC) is an aggressive and rare subtype of salivary gland carcinoma. Surgical excision and radiotherapy are standard of care for early cancer. Chemotherapies with taxanes and platinum show overall response rates between 39% and 50%. SDCs are often associated with an overexpression of the androgen receptor (AR) and HER2/neu which have recently become druggable targets. Case Presentation Here, we report on an 84-year-old male patient with metastatic SDC of the right parotid gland. In 2017, he underwent a right total parotidectomy, a right neck dissection, and an infratemporal fossa clearance followed by 6 weeks of radiotherapy. In 2018, due to metastatic spread in the lungs, bones, and pararenal gland, a pathological workup of the tumor tissue was performed and revealed both AR and HER2 overexpression, respectively. Consequently, he underwent androgen deprivation therapy and, due to asymptomatic progression, sequentially human epidermal growth factor receptor 2 (HER-2)-targeted therapy with ado-trastuzumab emtansine and neratinib, which led to stable disease during the course of about 18 months. The electronically captured patient-reported outcome had demonstrated a good tolerance of all three therapeutic lines. Conclusion In conclusion, since effective standard therapeutic treatment options for SDC may often not be tolerable in older patients, the implementation of personalized and adaptive treatments, especially in patients with rare tumor types, might offer valuable treatment options.
Collapse
Affiliation(s)
- Nora Asper
- University of Zurich, Zurich, Switzerland
| | | | | | | | | | | | | |
Collapse
|
5
|
Asmis LM, Serra A, Krafft A, Licht A, Leisinger E, Henschkowski-Serra J, Ganter MT, Hauptmann S, Tinguely M, Kremer Hovinga JA. Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura. N Engl J Med 2022; 387:2356-2361. [PMID: 36546627 DOI: 10.1056/nejmoa2211113] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
A 27-year-old patient with a history of severe obstetrical complications and arterial thrombosis received a diagnosis of hereditary thrombotic thrombocytopenic purpura (TTP) due to severe ADAMTS13 deficiency when she presented with an acute episode in the 30th week of her second pregnancy. When the acute episode of hereditary TTP became plasma-refractory and fetal death was imminent, weekly injections of recombinant ADAMTS13 at a dose of 40 U per kilogram of body weight were initiated. The patient's platelet count normalized, and the growth of the fetus stabilized. At 37 weeks 1 day of gestation, a small-for-gestational-age boy was delivered by cesarean section. At the time of this report, the patient and her son were well, and she continued to receive injections of recombinant ADAMTS13 every 2 weeks. (Funded by the Swiss National Science Foundation.).
Collapse
Affiliation(s)
- Lars M Asmis
- From Zentrum für Perioperative Thrombose und Hämostase (L.M.A.), Nephrology and Dialysis (A.S., J.H.-S.), Obstetrics and Gynecology (A.K.), Emergency Center (A.L.), and Institute for Anesthesiology and Intensive Care (E.L., M.T.G.), Hirslanden Clinic (L.M.A.), the Institute of Pathology Enge and Muensterlingen (S.H., M.T.), and the Medical Faculty, University of Zurich (L.M.A., A.S., A.K., A.L., M.T.G., M.T.), Zurich, and the Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern (J.A.K.H.) - all in Switzerland
| | - Andreas Serra
- From Zentrum für Perioperative Thrombose und Hämostase (L.M.A.), Nephrology and Dialysis (A.S., J.H.-S.), Obstetrics and Gynecology (A.K.), Emergency Center (A.L.), and Institute for Anesthesiology and Intensive Care (E.L., M.T.G.), Hirslanden Clinic (L.M.A.), the Institute of Pathology Enge and Muensterlingen (S.H., M.T.), and the Medical Faculty, University of Zurich (L.M.A., A.S., A.K., A.L., M.T.G., M.T.), Zurich, and the Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern (J.A.K.H.) - all in Switzerland
| | - Alexander Krafft
- From Zentrum für Perioperative Thrombose und Hämostase (L.M.A.), Nephrology and Dialysis (A.S., J.H.-S.), Obstetrics and Gynecology (A.K.), Emergency Center (A.L.), and Institute for Anesthesiology and Intensive Care (E.L., M.T.G.), Hirslanden Clinic (L.M.A.), the Institute of Pathology Enge and Muensterlingen (S.H., M.T.), and the Medical Faculty, University of Zurich (L.M.A., A.S., A.K., A.L., M.T.G., M.T.), Zurich, and the Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern (J.A.K.H.) - all in Switzerland
| | - Abraham Licht
- From Zentrum für Perioperative Thrombose und Hämostase (L.M.A.), Nephrology and Dialysis (A.S., J.H.-S.), Obstetrics and Gynecology (A.K.), Emergency Center (A.L.), and Institute for Anesthesiology and Intensive Care (E.L., M.T.G.), Hirslanden Clinic (L.M.A.), the Institute of Pathology Enge and Muensterlingen (S.H., M.T.), and the Medical Faculty, University of Zurich (L.M.A., A.S., A.K., A.L., M.T.G., M.T.), Zurich, and the Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern (J.A.K.H.) - all in Switzerland
| | - Elke Leisinger
- From Zentrum für Perioperative Thrombose und Hämostase (L.M.A.), Nephrology and Dialysis (A.S., J.H.-S.), Obstetrics and Gynecology (A.K.), Emergency Center (A.L.), and Institute for Anesthesiology and Intensive Care (E.L., M.T.G.), Hirslanden Clinic (L.M.A.), the Institute of Pathology Enge and Muensterlingen (S.H., M.T.), and the Medical Faculty, University of Zurich (L.M.A., A.S., A.K., A.L., M.T.G., M.T.), Zurich, and the Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern (J.A.K.H.) - all in Switzerland
| | - Jana Henschkowski-Serra
- From Zentrum für Perioperative Thrombose und Hämostase (L.M.A.), Nephrology and Dialysis (A.S., J.H.-S.), Obstetrics and Gynecology (A.K.), Emergency Center (A.L.), and Institute for Anesthesiology and Intensive Care (E.L., M.T.G.), Hirslanden Clinic (L.M.A.), the Institute of Pathology Enge and Muensterlingen (S.H., M.T.), and the Medical Faculty, University of Zurich (L.M.A., A.S., A.K., A.L., M.T.G., M.T.), Zurich, and the Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern (J.A.K.H.) - all in Switzerland
| | - Michael T Ganter
- From Zentrum für Perioperative Thrombose und Hämostase (L.M.A.), Nephrology and Dialysis (A.S., J.H.-S.), Obstetrics and Gynecology (A.K.), Emergency Center (A.L.), and Institute for Anesthesiology and Intensive Care (E.L., M.T.G.), Hirslanden Clinic (L.M.A.), the Institute of Pathology Enge and Muensterlingen (S.H., M.T.), and the Medical Faculty, University of Zurich (L.M.A., A.S., A.K., A.L., M.T.G., M.T.), Zurich, and the Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern (J.A.K.H.) - all in Switzerland
| | - Steffen Hauptmann
- From Zentrum für Perioperative Thrombose und Hämostase (L.M.A.), Nephrology and Dialysis (A.S., J.H.-S.), Obstetrics and Gynecology (A.K.), Emergency Center (A.L.), and Institute for Anesthesiology and Intensive Care (E.L., M.T.G.), Hirslanden Clinic (L.M.A.), the Institute of Pathology Enge and Muensterlingen (S.H., M.T.), and the Medical Faculty, University of Zurich (L.M.A., A.S., A.K., A.L., M.T.G., M.T.), Zurich, and the Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern (J.A.K.H.) - all in Switzerland
| | - Marianne Tinguely
- From Zentrum für Perioperative Thrombose und Hämostase (L.M.A.), Nephrology and Dialysis (A.S., J.H.-S.), Obstetrics and Gynecology (A.K.), Emergency Center (A.L.), and Institute for Anesthesiology and Intensive Care (E.L., M.T.G.), Hirslanden Clinic (L.M.A.), the Institute of Pathology Enge and Muensterlingen (S.H., M.T.), and the Medical Faculty, University of Zurich (L.M.A., A.S., A.K., A.L., M.T.G., M.T.), Zurich, and the Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern (J.A.K.H.) - all in Switzerland
| | - Johanna A Kremer Hovinga
- From Zentrum für Perioperative Thrombose und Hämostase (L.M.A.), Nephrology and Dialysis (A.S., J.H.-S.), Obstetrics and Gynecology (A.K.), Emergency Center (A.L.), and Institute for Anesthesiology and Intensive Care (E.L., M.T.G.), Hirslanden Clinic (L.M.A.), the Institute of Pathology Enge and Muensterlingen (S.H., M.T.), and the Medical Faculty, University of Zurich (L.M.A., A.S., A.K., A.L., M.T.G., M.T.), Zurich, and the Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern (J.A.K.H.) - all in Switzerland
| |
Collapse
|
6
|
Karamitopoulou E, Andreou A, Pahud de Mortanges A, Tinguely M, Gloor B, Perren A. PD-1/PD-L1-Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups. Cancer Immunol Res 2021; 9:1439-1450. [PMID: 34526323 DOI: 10.1158/2326-6066.cir-21-0144] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Revised: 05/21/2021] [Accepted: 09/10/2021] [Indexed: 11/16/2022]
Abstract
Immunotherapy, including PD-1/PD-L1 agonists, has shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC). We examined the PD-1/PD-L1 expression and immunoarchitectural features by automated morphometric analysis using multiplex immunofluorescence and 118 microsatellite-stable, treatment-naïve, surgically resected PDACs (study cohort). Five microsatellite-instable cases were stained in parallel (MSI cohort). Molecular analysis was additionally performed. An independent PDAC cohort (n = 226) was immunostained for PD-L1 and used as a validation cohort. PD-L1 expression on tumor cells (TC) and/or immune cells (IC) was present in 32% and 30% of the study and validation cohorts, respectively, and assigned into one of four patterns: "adaptive-1" (TC: 0, IC > 1%), "adaptive-2" (TC > 1% to < 25%, IC > 1%), "constitutive" (TC ≥ 25%, IC: 0), and "combined" (TC ≥ 25%, IC > 1%). "Constitutive" tumors were characterized by reduced numbers of all ICs and poor outcome. In contrast, "adaptive-1" tumors exhibited abundant T cells, including high counts of cytotoxic CD3+CD8+ and PD-1+CD3+CD8+ cells, but low counts of PD-L1+CD3+CD8+ cells and associated with the best outcome. "Adaptive-2" tumors displayed higher proportions of PD-L1+CD3+CD8+ T cells and tumor-associated macrophages (CD68+ and CD68+CD206+) compared with "adaptive-1" tumors. In the "combined" pattern, extensive PD-L1 expression on TCs was accompanied by increased numbers of T cells and improved overall survival. ICs were closer to PD-L1- than to PD-L1+ PDAC cells. TP53 and PIK3CA alterations tended to be more frequent in PD-L1+ tumors. The 5 MSI cases were PD-L1- The distinct PD-1/PD-L1-associated immunoarchitectural patterns underpin the heterogeneity of the immunologic responses and might be used to inform patient outcomes and therapeutic decisions in pancreatic cancer.
Collapse
Affiliation(s)
- Eva Karamitopoulou
- Institute of Pathology, University of Bern, Bern, Switzerland.
- Pathology Institute Enge, Zurich, Switzerland
| | - Andreas Andreou
- Department of Visceral Surgery, Insel University Hospital, University of Bern, Bern, Switzerland
| | | | | | - Beat Gloor
- Department of Visceral Surgery, Insel University Hospital, University of Bern, Bern, Switzerland
| | - Aurel Perren
- Institute of Pathology, University of Bern, Bern, Switzerland
| |
Collapse
|
7
|
Chea V, Pleiner V, Schweizer V, Herzog B, Bode B, Tinguely M. Optimized workflow for digitalized FISH analysis in pathology. Diagn Pathol 2021; 16:42. [PMID: 33975608 PMCID: PMC8114497 DOI: 10.1186/s13000-021-01103-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Accepted: 04/26/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Effective workflow management in a diagnostic pathology laboratory is critical to achieve rapid turnover while maintaining high quality. Fluorescence in situ hybridization analysis (FISH) is the preferred technique for detecting single chromosomal aberrations in diagnostic surgical pathology. MATERIAL AND METHODS FISH analysis applying a rapid hybridization protocol and using an automated whole-slide fluorescence scanning device (3DHISTECH, Sysmex, Switzerland) were implemented in our workflow. By analyzing 42 diagnostic cases, effects of two different scanning profiles on scanning time, and device memory usage were investigated. Manual signal counting (CaseViewer) and software based signal counting (FISHQuant) were compared. RESULTS The two scanning profiles, both including a Z-stack function, differed in their exposure time and digital gain. The "low profile" setting (LP) resulted in a significantly shorter scanning time and lower storage volume compared to the "high profile" (HP) setting, making the LP ideal for routine applications. Both signal counting methods (manual versus software based) provided similar cut-offs on a test-cohort of 13 samples. CONCLUSION Scanning FISH slides provides good picture quality, reduces the analysis time and allows easy picture archiving and facilitates remote diagnostics, allowing an effective workflow.
Collapse
Affiliation(s)
- Vira Chea
- Institute of Pathology Enge, Hardturmstr. 133, CH-8055, Zurich, Switzerland
| | - Valerie Pleiner
- Institute of Pathology Enge, Hardturmstr. 133, CH-8055, Zurich, Switzerland
| | - Viviane Schweizer
- Institute of Pathology Enge, Hardturmstr. 133, CH-8055, Zurich, Switzerland
| | | | - Beata Bode
- Institute of Pathology Enge, Hardturmstr. 133, CH-8055, Zurich, Switzerland
| | - Marianne Tinguely
- Institute of Pathology Enge, Hardturmstr. 133, CH-8055, Zurich, Switzerland.
| |
Collapse
|
8
|
Güth U, Borovecki A, Amann E, Rechsteiner M, Tinguely M. Pleomorphic lobular breast carcinoma with osteoclast like giant cells in the era of genomic testing. Current Problems in Cancer: Case Reports 2020. [DOI: 10.1016/j.cpccr.2020.100008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
9
|
Schaumann N, Raap M, Hinze L, Rieger L, Schürch CM, Antonopoulos W, Avril S, Krech T, Dämmrich M, Kayser G, Puls F, Länger F, Tinguely M, Kreipe H, Christgen M. Lobular neoplasia and invasive lobular breast cancer: Inter-observer agreement for histological grading and subclassification. Pathol Res Pract 2019; 215:152611. [PMID: 31551174 DOI: 10.1016/j.prp.2019.152611] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Revised: 08/19/2019] [Accepted: 08/19/2019] [Indexed: 12/01/2022]
Abstract
Lobular neoplasia (LN), invasive lobular breast cancer (ILBC) and related pleomorphic variants represent a distinct group of neoplastic mammary gland lesions. This study assessed the inter-observer agreement of histological grading in a series of ILBC and LN. 54 cases (36x ILBC, 18x LN) were evaluated by 17 observers. 3978 classification calls on various histological features, including nuclear grade, proliferative activity (Ki67 immunohistochemistry, categorical scoring), histological grade and pleomorphism were obtained. Pairwise Cohen's kappa values were calculated and compared between various features and different observer subsets with variable histomorphological experience. In ILBC, pairwise inter-observer agreement for histological grade ranged from poor to almost perfect concordance and was higher in advanced and experienced histopathologists compared with beginners (P < 0.001). Agreement for proliferation (Ki67) ranged from slight to almost perfect concordance and was also higher in advanced and experienced histopathologists (P < 0.001). Considering different features, agreement for proliferation (Ki67) was superior to agreement for histological grade and nuclear grade, even among advanced and experienced histopathologists (P < 0.001). In LN, agreement for B-classification ranged from poor to almost perfect concordance and was higher in advanced and experienced histopathologists (P < 0.001). Considering different features, agreement for proliferation (Ki67 in LN) was superior to subclassification agreement based on conventional features, such as acinar distention and nuclear grade (P < 0.001). In summary, pairwise inter-observer concordance of histological grading of ILBC and LN is dependent on histomorphological experience. Assessment of proliferation by Ki67 immunohistochemistry is associated with favorable inter-observer agreement and can improve histological grading of ILBC as well as LN.
Collapse
Affiliation(s)
- Nora Schaumann
- Institute of Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
| | - Mieke Raap
- Institute of Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
| | - Laura Hinze
- Institute of Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
| | - Luisa Rieger
- Institute of Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
| | - Christian M Schürch
- Institute of Pathology, University of Bern, Murtenstr. 31, 3008 Bern, Switzerland
| | - Wiebke Antonopoulos
- Institute of Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
| | - Stefanie Avril
- Department of Pathology, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, 10900 Euclid Ave., Cleveland, OH 44106-7288, USA
| | - Till Krech
- Institute of Pathology, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
| | - Maximilian Dämmrich
- Gemeinschaftspraxis für Pathologie, Alte Bahnhofstr. 1, 97422 Schweinfurt, Germany
| | - Gian Kayser
- Institute of Surgical Pathology, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Breisacher Str. 115a, 79106 Freiburg, Germany
| | - Florian Puls
- Department of Pathology and Genetics, University of Gothenburg, Gula Stråket 8, 413 46 Göteborg, Sweden
| | - Florian Länger
- Institute of Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
| | - Marianne Tinguely
- Institute of Pathology Enge, Hardturmstrasse 133, 8005 Zürich, Switzerland
| | - Hans Kreipe
- Institute of Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
| | - Matthias Christgen
- Institute of Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
| |
Collapse
|
10
|
Papassotiropoulos B, Güth U, Chiesa F, Rageth C, Amann E, Baege A, Elfgen C, Varga Z, Moskovszky L, Endhardt K, Masser R, Tinguely M, Farhadi J, Lardi A, Dammann F, Diebold J, Li Q, Dubsky P, Tausch C. Prospective Evaluation of Residual Breast Tissue After Skin- or Nipple-Sparing Mastectomy: Results of the SKINI-Trial. Ann Surg Oncol 2019; 26:1254-1262. [PMID: 30830538 DOI: 10.1245/s10434-019-07259-1] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2019] [Indexed: 11/18/2022]
Abstract
OBJECTIVE This study was designed to investigate the presence of residual breast tissue (RBT) after skin-sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM) and to analyse patient- and therapy-related factors associated with RBT. Skin-sparing mastectomy and NSM are increasingly used surgical procedures. Prospective data on the completeness of breast tissue resection is lacking. However, such data are crucial for assessing oncologic safety of risk-reducing and curative mastectomies. METHODS Between April 2016 and August 2017, 99 SSM and 61 NSM were performed according to the SKINI-trial protocol, under either curative (n = 109) or risk-reducing (n = 51) indication. After breast removal, biopsies from the skin envelope (10 biopsies per SSM, 14 biopsies per NSM) were taken in predefined radial localizations and assessed histologically for the presence of RBT and of residual disease. RESULTS Residual breast tissue was detected in 82 (51.3%) mastectomies. The median RBT percentage per breast was 7.1%. Of all factors considered, only type of surgery (40.4% for SSM vs. 68.9% for NSM; P < 0.001) and surgeon (P < 0.001) were significantly associated with RBT. None of the remaining factors, e.g., skin flap necrosis, was associated significantly with RBT. Residual disease was detected in three biopsies. CONCLUSIONS Residual breast tissue is commonly observed after SSM and NSM. In contrast, invasive or in situ carcinomas are rarely found in the skin envelope. Radicality of mastectomy in this trial is not associated with increased incidence of skin flap necrosis. ClinicalTrials.gov Identifier NCT03470909.
Collapse
Affiliation(s)
| | - Uwe Güth
- Department of Breast Surgery, Brust-Zentrum, Zurich, Switzerland
| | - Federica Chiesa
- Department of Breast Surgery, Brust-Zentrum, Zurich, Switzerland
| | - Christoph Rageth
- Department of Breast Surgery, Brust-Zentrum, Zurich, Switzerland
| | - Esther Amann
- Department of Breast Surgery, Brust-Zentrum, Zurich, Switzerland
| | - Astrid Baege
- Department of Breast Surgery, Brust-Zentrum, Zurich, Switzerland
| | - Constanze Elfgen
- Department of Breast Surgery, Brust-Zentrum, Zurich, Switzerland
| | - Zsuzsanna Varga
- Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Linda Moskovszky
- Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Katharina Endhardt
- Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
| | | | | | - Jian Farhadi
- Department of Plastic Surgery, Brust-Zentrum, Zurich, Switzerland
| | - Alessia Lardi
- Department of Plastic Surgery, Brust-Zentrum, Zurich, Switzerland
| | | | | | - Qiyu Li
- Statistician Unit, Swiss Group for Clinical Cancer Research, Bern, Switzerland
| | - Peter Dubsky
- Breast Center, Hirslanden Clinic St. Anna, Lucerne, Switzerland.,Department of Surgery, Medical University of Vienna, Vienna, Austria
| | - Christoph Tausch
- Department of Breast Surgery, Brust-Zentrum, Zurich, Switzerland
| |
Collapse
|
11
|
Bornstein MM, Claude A, Meier T, Tinguely M. [Peripheral giant-cell granuloma in peri-implant tissues]. Swiss Dent J 2018; 128:980-981. [PMID: 30525321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- Michael M. Bornstein
- Klinik für Oralchirurgie und Stomatologie, Zahnmedizinische Kliniken der Universität Bern
- Oro-faziales Diagnostikzentrum Weinbergstrasse, Zürich
| | | | | | | |
Collapse
|
12
|
Tausch C, Papassotiropoulos B, Chiesa F, Rageth C, Amann E, Güth U, Baege A, Elfgen C, Masser R, Tinguely M, Farhadi J, Lardi A, Damann F, Varga Z, Moskovszky L, Endhardt K, Joachim D, Li Q, Dubsky P. Prospective evaluation of residual breast tissue after skin- or nipple-sparing mastectomy – results of the SKINI-trial. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30279-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
13
|
Steiner R, Kridel R, Giostra E, McKee T, Achermann R, Mueller N, Manuel O, Dickenmann M, Schuurmans MM, de Leval L, Fehr T, Tinguely M, Binet I, Cogliatti S, Haralamvieva E, Koller M, The Swiss Transplant Cohort Study Stcs, Dietrich PY. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland. Swiss Med Wkly 2018. [PMID: 29518251 DOI: 10.4414/smw.2018.14596] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Post-transplant lymphoproliferative disorder (PTLD) is a potentially life-threatening complication of transplantation occurring in the setting of immunosuppression and oncogenic viral infections. However, little is known about the cumulative incidence, histological subtypes, risk determinants and outcome of PTLD in solid organ transplant (SOT) recipients in Switzerland. METHODS This retrospective observational study investigated adult SOT recipients from two sequential cohorts, the pre-SCTS (Swiss Transplant Cohort Study) series, with data collected from January 1986 to April 2008, and the STCS series, with data collected from May 2008 to December 2014 in Switzerland. SOT recipients were cross-referenced with the data of all the patients with a lymphoma diagnosis in each transplant centre and with the data of the Swiss Transplant Cohort Study (STCS) to determine the cumulative incidence of PTLD, pre-therapeutic clinical features, clinical course and outcome. Kaplan-Meier analysis was performed for overall survival after PTLD. RESULTS We identified 79 cases of PTLD during the study period in the two cohorts: pre-STCS from 1986 to 2008 (n = 62) and STCS from 2008 to 2014 (n = 17). Histological subgroups included: early lesions (pre-STCS n = 2, STCS n = 0); polymorphic PTLD (pre-STCS n = 8, STCS n = 7); monomorphic PTLD (pre-STCS n = 47, STCS n = 10), and Hodgkin's lymphoma (pre-STCS n = 5, STCS n = 0). Median time to PTLD diagnosis was 90 months (range 3-281 months) and 14 months (range 2-59 months) in the pre-STCS and STCS cohorts, respectively. Median follow-up after transplantation was 141 months for the pre-STCS patients and 33 months for the STCS patients. Cumulative incidences of PTLD during the STCS period at 0.5, 1 and 5 years were 0.17% (95% confidence interval 0.07-0.46%), 0.22% (0.09-0.53%) and 0.96% (0.52-1.80%), respectively. For the pre-STCS case series, it was not possible to estimate the incidence rate of PTLD. Survival after PTLD diagnosis was 80% (68-87%) at 1 year and 56% (42-68%) at 5 years for the pre-STCS and STCS cohorts combined. CONCLUSIONS At 5 years, the cumulative incidence of PTLD, regardless of the organ transplanted, was only 0.96% in the STCS cohort, which is lower than that reported in the literature.
Collapse
Affiliation(s)
- Raphael Steiner
- Centre of Oncology, University Hospitals of Geneva, Switzerland
| | - Robert Kridel
- Princess Margaret Cancer Centre - UHN, Toronto, Ontario, Canada
| | - Emiliano Giostra
- Hepatogastroenterology, Geneva University Hospital, Geneva, Switzerland
| | - Thomas McKee
- Division of Haematology, Department of Patho-Immunology, Geneva University Medical Centre, Geneva, Switzerland
| | | | - Nicolas Mueller
- Swiss Transplant Cohort Study (STCS) / Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, Switzerland
| | - Oriol Manuel
- Swiss Transplant Cohort Study (STCS) / Infectious Disease Service, Department of Medicine, Lausanne University Hospital (CHUV), Switzerland
| | - Michael Dickenmann
- Swiss Transplant Cohort Study (STCS) / Division of Transplantation Immunology and Nephrology, Basel University Hospital, Switzerland
| | | | - Laurence de Leval
- Institute of Pathology, Lausanne University Hospital (CHUV), Switzerland
| | - Thomas Fehr
- Department of Internal Medicine, Cantonal Hospital Graubuenden, Chur,and Division of Nephrology, University Hospital Zurich, Switzerland
| | | | - Isabelle Binet
- Swiss Transplant Cohort Study (STCS) / Nephrology/Transplantation Medicine, Kantonsspital, St Gallen, Switzerland
| | | | | | | | | | | |
Collapse
|
14
|
De Souza A, Tinguely M, Burghart DR, Berisha A, Mertz KD, Kempf W. Characterization of the tumor microenvironment in primary cutaneous CD30-positive lymphoproliferative disorders: a predominance of CD163-positive M2 macrophages. J Cutan Pathol 2016; 43:579-88. [PMID: 27080437 DOI: 10.1111/cup.12719] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Revised: 01/13/2016] [Accepted: 04/11/2016] [Indexed: 12/16/2022]
Abstract
BACKGROUND The tumor microenvironment is essential for tumor survival, growth and progression. There are only a few studies on the tumor microenvironment in cutaneous CD30-positive lymphoproliferative disorders. METHODS We assessed the composition of the tumor microenvironment using immunohistochemistry studies in skin biopsies from cases diagnosed with lymphomatoid papulosis (LyP: 18 specimens), primary cutaneous anaplastic large-cell lymphoma (PC-ALCL: 8 specimens), and reactive diseases harboring CD30-positive cells (18 specimens). RESULTS The predominant cells present in LyP and PC-ALCL were CD163+ M2 macrophages (44.7%, 35%), followed by CD8+ tumor infiltrating lymphocytes (11%, 15%), FOXP3+ T-regulatory cells (9%, 4.5%) and programmed cell death 1(PD-1) + lymphocytes (2.2%, 6.8%). In contrast, CD30-positive reactive inflammatory and infectious disorders were characterized by higher numbers of CD123+ plasmacytoid dendritic cells (6.3%) when compared to LyP (1%), and PC-ALCL (1.1%). CONCLUSIONS Key differences exist between the microenvironment of CD30-positive lymphoproliferative disorders and reactive conditions harboring CD30-positive lymphocytes. The high number of tumor associated macrophages, and the close vicinity of these immune cells to the CD30-positive tumor cells might suggest that tumor associated macrophages have direct influence on tumorigenesis in LyP and ALCL. Therefore, modulation of M2 macrophages may represent a new therapeutic strategy in cutaneous CD30-positive lymphoproliferative disorders.
Collapse
Affiliation(s)
- Aieska De Souza
- Kempf and Pfaltz Histologische Diagnostik, Zürich, Switzerland.,Department of Dermatology, Harvard Medical School, Boston, MA, USA
| | | | - Daniel R Burghart
- Kempf and Pfaltz Histologische Diagnostik, Zürich, Switzerland.,Department of Economics, California State University Sacramento, Sacramento, CA, USA
| | | | - Kirsten D Mertz
- Institute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland
| | - Werner Kempf
- Kempf and Pfaltz Histologische Diagnostik, Zürich, Switzerland
| |
Collapse
|
15
|
Varshney A, Goyal T, Zawar V, Tinguely M, Kempf W. Disseminated anetoderma in a patient with nodal Epstein-Barr virus-associated classical Hodgkin lymphoma: Anetodermic form of a concurrent discordant cutaneous marginal zone lymphoma. Int J Dermatol 2016; 55:739-44. [DOI: 10.1111/ijd.13262] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/16/2015] [Revised: 11/09/2015] [Accepted: 11/18/2015] [Indexed: 11/29/2022]
Affiliation(s)
- Anupam Varshney
- Department of Pathology; Muzaffarnagar Medical College & Hospital; Muzaffarnagar Uttar Pradesh
| | - Tarang Goyal
- Department of Dermatology; Muzaffarnagar Medical College & Hospital; Muzaffarnagar Uttar Pradesh
| | - Vijay Zawar
- Consultant Dermatologist; Skin Diseases Centre Nashik; India
| | - Marianne Tinguely
- Kempf und Pfaltz Histologische Diagnostik; Research Unit; Zurich Switzerland
| | - Werner Kempf
- Kempf und Pfaltz Histologische Diagnostik; Research Unit; Zurich Switzerland
| |
Collapse
|
16
|
Hofmann A, Thiesler T, Gerrits B, Behnke S, Sobotzki N, Omasits U, Bausch-Fluck D, Bock T, Aebersold R, Moch H, Tinguely M, Wollscheid B. Surfaceome of classical Hodgkin and non-Hodgkin lymphoma. Proteomics Clin Appl 2016; 9:661-70. [PMID: 26076441 DOI: 10.1002/prca.201400146] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2014] [Revised: 03/09/2015] [Accepted: 06/10/2015] [Indexed: 11/06/2022]
Abstract
PURPOSE Classical Hodgkin lymphoma (cHL) is characterized by a low percentage of tumor cells in a background of diverse, reactive immune cells. cHL cells commonly derive from preapoptotic germinal-center B cells and are characterized by the loss of B-cell markers and the varying expression of other hematopoietic lineage markers. This phenotypic variability and the scarcity of currently available cHL-specific cell surface markers can prevent clear distinction of cHL from related lymphomas. EXPERIMENTAL DESIGN We applied the cell surface capture technology to directly measure the pool of cell surface exposed proteins in four cHL and four non-Hodgkin lymphoma (NHL) cell lines. RESULTS More than 1000 membrane proteins, including 178 cluster of differentiation annotated proteins, were identified and allowed the generation of lymphoma surfaceome maps. The functional properties of identified cell surface proteins enable, but also limit the information exchange of lymphoma cells with their microenvironment. CONCLUSION AND CLINICAL RELEVANCE Selected candidate proteins with potential diagnostic value were evaluated on a tissue microarray (TMA). Primary lymphoma tissues of 126 different B cell-derived lymphoma cases were included in the TMA analysis. The TMA analysis indicated gamma-glutamyltranspeptidase 1 as a potential additional marker that can be included in a panel of markers for differential diagnosis of cHL versus NHL.
Collapse
Affiliation(s)
- Andreas Hofmann
- Department of Biology, Institute of Molecular Systems Biology, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland.,Ph.D. Program in Molecular Life Sciences, University of Zurich (UZH)/ETH Zurich, Zurich, Switzerland
| | - Thore Thiesler
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Bertran Gerrits
- Functional Genomics Center Zurich, UZH/ETH Zurich, Zurich, Switzerland
| | - Silvia Behnke
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Nadine Sobotzki
- Department of Biology, Institute of Molecular Systems Biology, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland.,Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
| | - Ulrich Omasits
- Department of Biology, Institute of Molecular Systems Biology, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland
| | - Damaris Bausch-Fluck
- Department of Biology, Institute of Molecular Systems Biology, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland.,Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
| | - Thomas Bock
- Department of Biology, Institute of Molecular Systems Biology, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland
| | - Ruedi Aebersold
- Department of Biology, Institute of Molecular Systems Biology, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland.,Faculty of Science, UZH, Zurich, Switzerland
| | - Holger Moch
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Marianne Tinguely
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Bernd Wollscheid
- Department of Biology, Institute of Molecular Systems Biology, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland.,Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
| |
Collapse
|
17
|
Eppler E, Janas E, Link K, Weidmann L, Bischofberger H, Wenger M, Tinguely M, Schraml P, Moch H, Fellbaum C. Insulin-like growth factor I is expressed in classical and nodular lymphocyte-predominant Hodgkin’s lymphoma tumour and microenvironmental cells. Cell Tissue Res 2014; 359:841-51. [DOI: 10.1007/s00441-014-2052-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2014] [Accepted: 10/27/2014] [Indexed: 12/29/2022]
|
18
|
De Souza A, Tinguely M, Pfaltz M, Burghart DR, Kempf W. Loss of expression of 5-hydroxymethylcytosine in CD30-positive cutaneous lymphoproliferative disorders. J Cutan Pathol 2014; 41:901-6. [DOI: 10.1111/cup.12411] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2014] [Revised: 09/03/2014] [Accepted: 10/26/2014] [Indexed: 01/07/2023]
Affiliation(s)
- Aieska De Souza
- Department of Dermatology; Harvard Medical School; Boston MA USA
| | | | | | | | - Werner Kempf
- Kempf and Pfaltz; Histologische Diagnostik; Zürich Switzerland
| |
Collapse
|
19
|
Kempf W, Kazakov DV, Rütten A, Rupec RA, Talarcik P, Ballová V, Kerl K, Dummer R, Lautenschlager S, Zimmermann DR, Tinguely M. Primary cutaneous follicle center lymphoma with diffuse CD30 expression: A report of 4 cases of a rare variant. J Am Acad Dermatol 2014; 71:548-54. [DOI: 10.1016/j.jaad.2014.03.027] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Revised: 03/12/2014] [Accepted: 03/13/2014] [Indexed: 11/24/2022]
|
20
|
Rechsteiner M, Müller R, Reineke T, Goede J, Bohnert A, Zhong Q, Manz MG, Moch H, Wild PJ, Zimmermann DR, Tinguely M. Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing. Exp Hematol Oncol 2014; 3:18. [PMID: 25032071 PMCID: PMC4100747 DOI: 10.1186/2162-3619-3-18] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2014] [Accepted: 07/01/2014] [Indexed: 11/30/2022] Open
Abstract
Background Systemic mastocytosis (SM) is a heterogenous, clonal mast cell (MC) proliferation, rarely associated with clonal hematologic non-mast cell lineage disease (SM-AHNMD). KITD816V is regarded as driver-mutation in SM-AHNMD. Methods DNA isolated from peripheral blood (PB) of an SM-CMML patient was investigated with targeted next generation sequencing. Variants were verified by Sanger sequencing and further characterized in the SM part of the bone marrow trephine (BMT), normal tissue, and FACS sorted PB cell subpopulations. Findings Low coverage deep-sequencing (mean 10x) on a GS 454 Junior revealed two as yet unreported SNVs (CBFA2T3 and CLTCL1), both germ-line mutations. High coverage (mean 1674x) targeted re-sequencing on an Ion Proton revealed 177 variants in coding regions. Excluding SNPs, the final list comprised 11 variants. Among these, TET2 (p.Thr1027fs, p.Cys1263Ser) and RUNX1 (p.Asn109Ser) were identified in in the peripheral blood and the SM part of BMT, but not in normal tissue. Furthermore, Sanger sequencing of PB cells revealed similar signal intensities for both TET2 mutations in FACS sorted CD34+ precursor cells and CD16+ granulocytes comparable to signals in the SM part of BMT. In contrast, RUNX1 exhibited a double intensity in CD34+ cells compared to the SM part of BMT and a homozygous variant signal in granulocytes. Both TET2 and RUNX1 mutations were not detectable in B- and T-cells. Conclusion We present a heterozygous triple-mutation pattern (KIT, TET2, RUNX1) in mast cells (SM disease part) with additional LOH of RUNX1 in granulocytes (CMML disease part). These identified mutations allow a more detailed insight into a multistep pathogenesis which suggests a common tumor progenitor in SM-CMML.
Collapse
Affiliation(s)
- Markus Rechsteiner
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Rouven Müller
- Clinics for Hematology, University Hospital Zurich, Zurich, Switzerland
| | - Tanja Reineke
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Jeroen Goede
- Clinics for Hematology, University Hospital Zurich, Zurich, Switzerland
| | - Annette Bohnert
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Qing Zhong
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Markus G Manz
- Clinics for Hematology, University Hospital Zurich, Zurich, Switzerland
| | - Holger Moch
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Peter J Wild
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Dieter R Zimmermann
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Marianne Tinguely
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland ; Kempf and Pfaltz, Histological Diagnostics, Seminarstr. 1, 8042 Zurich, Switzerland
| |
Collapse
|
21
|
Curioni-Fontecedro A, Martin V, Vogetseder A, Knuth A, Moch H, Soldini D, Tinguely M. Chromosomal aberrations of cancer-testis antigens in myeloma patients. Hematol Oncol 2014; 33:159-63. [PMID: 24820892 DOI: 10.1002/hon.2143] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Revised: 03/10/2014] [Accepted: 03/12/2014] [Indexed: 12/26/2022]
Abstract
Cancer-testis antigens (CTAgs) play a major role in the immune response against cancer, but their biological functions in germ and cancer cells is still unclear. MAGE-C1 and MAGE-C2 are two CTAgs located at the Xq27 region of chromosome X and frequently expressed in multiple myeloma. Chromosomal rearrangements often occur in myeloma. We therefore investigated whether numerical and structural chromosomal aberrations correlate with their protein expression in primary multiple myelomas. To this aim, we designed new fluorescence in situ hybridization probes specific for the MAGE region in the Xq27 region and evaluated simultaneously aberrations of the X chromosome centromere. The comparison of MAGE copy number and chromosome X status revealed that MAGE copy number changes occurred in 6/43 (14%) cases, independent of concomitant X chromosome alterations. These numerical aberrations are less frequent than the expression of MAGE-C1 and MAGE-C2 (63% and 27% of patients, respectively) and do not always correlate with MAGE-C1 and MAGE-C2 expressions, suggesting alternative regulatory mechanisms in the expression of these genes.
Collapse
Affiliation(s)
| | | | - Alexander Vogetseder
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Alexander Knuth
- Departement of Oncology, University Hospital Zurich, Zurich, Switzerland
| | - Holger Moch
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Davide Soldini
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Marianne Tinguely
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland.,Kempf and Pfaltz, Histologische Diagnostik, Zurich, Switzerland
| |
Collapse
|
22
|
Brandt S, Montagna C, Georgis A, Schüffler PJ, Bühler MM, Seifert B, Thiesler T, Curioni-Fontecedro A, Hegyi I, Dehler S, Martin V, Tinguely M, Soldini D. The combined expression of the stromal markers fibronectin and SPARC improves the prediction of survival in diffuse large B-cell lymphoma. Exp Hematol Oncol 2013; 2:27. [PMID: 24499539 PMCID: PMC3852975 DOI: 10.1186/2162-3619-2-27] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2013] [Accepted: 09/30/2013] [Indexed: 01/01/2023] Open
Abstract
Background In diffuse large B-cell lymphomas, gene expression profiling studies attributed a major biologic role to non-neoplastic cells of the tumour microenvironment as its composition and characteristics were shown to predict survival. In particular, the expression of selected genes encoding components of the extracellular matrix was reported to be associated with clinical outcome. Nevertheless, the translation of these data into robust, routinely applicable immunohistochemical markers is still warranted. Therefore, in this study, we analysed the combination of the expression of the extracellular matrix components Fibronectin and SPARC on formalin-fixed paraffin embedded tissue derived from 173 patients with DLBCL in order to recapitulate gene expression profiling data. Results The expression of Fibronectin and SPARC was detected in 77/173 (44.5%) and 125/173 (72.3%) cases, respectively, and 55/173 (31.8%) cases were double positive. Patients with lymphomas expressing Fibronectin showed significantly longer overall survival when compared to negative ones (6.3 versus 3.6 years). Moreover, patients with double positive lymphomas also presented with significantly longer overall survival when compared with the remaining cases (11.6 versus 3.6 years) and this combined expression of both markers results in a better association with overall survival data than the expression of SPARC or Fibronectin taken separately (Hazard ratio 0.41, 95% confidence interval 0.17 to 0.95, p = 0.037). Finally, neither Fibronectin nor SPARC expression was associated with any of the collected clinico-pathological parameters. Conclusions The combined immunohistochemical assessment of Fibronectin and SPARC, two components of the extracellular matrix, represents an important tool for the prediction of survival in diffuse large B-cell lymphomas. Our study suggests that translation of gene expression profiling data on tumour microenvironment into routinely applicable immunohistochemical markers is a useful approach for a further characterization of this heterogeneous type of lymphoma.
Collapse
Affiliation(s)
- Simone Brandt
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Chiara Montagna
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Antoin Georgis
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | | | - Marco M Bühler
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Burkhardt Seifert
- Division of Biostatistics, Institute for Social and Preventive Medicine, University of Zurich, Zurich, Switzerland
| | - Thore Thiesler
- Institute of Pathology, University of Bonn, Bonn, Germany
| | | | - Ivan Hegyi
- Institute of Pathology, Locarno, Switzerland
| | - Silvia Dehler
- Cancer Registry, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | | | - Marianne Tinguely
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland.,Kempf and Pfaltz, Histologische Diagnostik, Zurich 8042, Switzerland
| | - Davide Soldini
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| |
Collapse
|
23
|
Soldini D, Georgis A, Montagna C, Schüffler PJ, Martin V, Curioni-Fontecedro A, Martinez A, Tinguely M. The combined expression of VPREB3 and ID3 represents a new helpful tool for the routine diagnosis of mature aggressive B-cell lymphomas. Hematol Oncol 2013; 32:120-5. [PMID: 24493312 DOI: 10.1002/hon.2094] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2013] [Revised: 08/08/2013] [Accepted: 08/12/2013] [Indexed: 11/10/2022]
Abstract
Genomic studies, such as gene expression profiling and next-generation sequencing studies, have provided new insights into the phenotypic characteristics and pathogenesis of mature aggressive B-cell lymphomas. In particular, mutations in the transcription factors ID3 and TCF3, leading to overexpression of B-cell receptor components such as VPREB3, have been shown to be specific for Burkitt lymphoma (BL) and play an important tumourigenic role by mediating the activation of the pro-survival phosphatidylinositol-3-OH kinase pathway. We performed immunohistochemical analysis by applying commercially available anti-VPREB3 antibody to a large cohort of 185 genetically and immunophenotypically characterized mature aggressive B-cell lymphomas and analyzed these results together with recent data on ID3 expression. The combined expression of both VPREB3 and ID3 was associated with a diagnosis of BL with high sensitivity (0.77), high specificity (0.75) and high negative predictive values (0.96), however, with lower positive predictive value (0.30). Double negative cases were absent in the group of BLs but could be found in approximately one third of the remaining cases of mature aggressive B-cell lymphomas. Further, we could not identify a correlation with MYC, BCL2 or BCL6 aberrations with neither VPREB3 nor ID3 expression in each of the diagnostic groups analyzed. Our results, which are in line with recently discovered mutations in next-generation sequencing studies, suggest that the combined immunohistochemical detection of VPREB3 and ID3 is applicable to the routine diagnostic in case of mature aggressive B-cell lymphomas. In particular, it represents a useful and routinely applicable diagnostic tool to exclude BL diagnosis in case of single positive or double negative cases.
Collapse
Affiliation(s)
- Davide Soldini
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Tinguely M. Immunosuppression-associated pathology. Pathobiology 2013; 80:273-4. [PMID: 24013713 DOI: 10.1159/000351126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
25
|
Abstract
Organ transplant recipients (OTR) are at a significantly increased risk for developing a wide variety of skin cancers, particularly epithelial skin cancer, Merkel cell carcinoma and Kaposi's sarcoma. Melanoma, skin adnexal neoplasm and cutaneous lymphomas are also more common in OTR and may differ in their clinicopathologic presentation from tumors in immunocompetent patients. The accuracy of clinical diagnosis of suspected premalignant and malignant skin lesions in OTR is modest. Therefore, histopathological diagnosis is an essential element for the diagnostic workup of skin cancers and, in addition, provides important information on prognosis. Squamous cell carcinoma and intraepithelial neoplasias (actinic keratosis, squamous cell carcinoma in situ or Bowen's disease) are the most common forms of skin cancer in OTR. The risk of Merkel cell carcinoma and Kaposi's sarcoma is dramatically increased in OTR. Merkel cell carcinoma shows a highly aggressive course. Kaposi's sarcoma tends to spread to extracutaneous sites. Primary cutaneous lymphomas developing after organ transplantation are rare. The spectrum of cutaneous B cell lymphomas in OTR, in particular, differs significantly from that of the general population, with a predominance of Epstein-Barr virus-driven posttransplant lymphoproliferative disorder. This review discusses the clinical and histopathological aspects of skin cancers in OTR, the impact of dermatopathological analysis on prognosis and the understanding of the pathogenesis of these neoplasms.
Collapse
Affiliation(s)
- Werner Kempf
- Kempf and Pfaltz Histological Diagnostics, Zurich, Switzerland
| | | | | | | |
Collapse
|
26
|
Tinguely M, Thies S, Frigerio S, Reineke T, Korol D, Zimmermann DR. IRF8 is associated with germinal center B-cell-like type of diffuse large B-cell lymphoma and exceptionally involved in translocation t(14;16)(q32.33;q24.1). Leuk Lymphoma 2013; 55:136-42. [PMID: 23573829 DOI: 10.3109/10428194.2013.793324] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Chromosomal translocations involving the immunoglobulin loci represent frequent oncogenic events in B-cell lymphoma development. Although IRF8 (ICSBP-1) protein expression has been demonstrated in germinal center B-cells and related lymphomas in a single report, the IRF8 gene was not described as an immunoglobulin heavy chain (IGH) translocation partner. In a discovery-driven approach we searched for new translocation partners of IGH in diffuse large B-cell lymphoma (DLBCL) by long distance inverse polymerase chain reaction (LDI-PCR) and Sanger sequencing. A t(14;16)(q32.33;q24.1) IGH/IRF8 was detected in a CD5+de novo DLBCL, confirmed by translocation specific PCR and fluorescence in situ hybridization (FISH) analysis. No further IRF8 aberration could be identified either by LDI-PCR in an additional five CD5+DLBCLs or by FISH on 78 formalin-fixed paraffin-embedded biopsies. Subsequent screening for IRF8 by immunohistochemistry revealed IRF8 expression in 18/78 (23%), correlating with a germinal center B-cell-like (GCB) type of DLBCL. This hitherto unknown translocation t(14;16)(q32.33;q24.1) is likely to represent the initiator of a multistep lymphomagenesis in a CD5+de novo DLBCL.
Collapse
Affiliation(s)
- Marianne Tinguely
- Institute of Surgical Pathology, University Hospital Zurich , Zurich , Switzerland
| | | | | | | | | | | |
Collapse
|
27
|
Abstract
The rapid technological development in diagnostic pathology, especially of immunohistochemical and molecular techniques, also has a significant impact on diagnostic procedures for the evaluation of bone marrow trephine biopsies. The necessity for optimal morphology, combined with preservation of tissue antigens and nucleic acids on one hand and the wish for short turnaround times on the other hand require careful planning of the workflow for fixation, decalcification and embedding of trephines. Although any kind of bone marrow processing has its advantages and disadvantages, formalin fixation followed by EDTA decalcification can be considered a good compromise, which does not restrict the use of molecular techniques. Although the majority of molecular studies in haematological neoplasms are routinely performed on bone marrow aspirates or peripheral blood cells, there are certain indications, in which molecular studies such as clonality determination or detection of specific mutations need to be performed on the trephine biopsy. Especially, the determination of B- or T-cell clonality for the diagnosis of lymphoid malignancies requires stringent quality controls and knowledge of technical pitfalls. In this review, we discuss technical aspects of bone marrow biopsy processing and the application of diagnostic molecular techniques.
Collapse
Affiliation(s)
- L Quintanilla-Martinez
- Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Liebermeisterstr 8, 72076 Tübingen, Deutschland.
| | | | | | | |
Collapse
|
28
|
Camicia R, Bachmann SB, Winkler HC, Beer M, Tinguely M, Haralambieva E, Hassa PO. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-53 axes in diffuse large B-cell lymphoma. J Cell Sci 2013; 126:1969-80. [DOI: 10.1242/jcs.118174] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The B-aggressive lymphoma-1 protein and ADP-ribosyltransferase BAL1/ARTD9 has been recently identified as a novel risk-related gene product in aggressive diffuse large B-cell lymphoma (DLBCL). BAL1 is constitutively expressed in a subset of high-risk DLBCL with an active host inflammatory response and suggested to be associated with interferon related gene expression. Here we identify BAL1 as a novel oncogenic survival factor in DLBCL and show that constitutive overexpression of BAL1 in DLBCL tightly associates with intrinsic interferon-gamma (IFNγ) signaling and constitutive activity of signal transducer and activator of transcription (STAT)-1. Remarkably, BAL1 stimulates the phosphorylation of both STAT1 isoforms STAT1α and STAT1β, on Y701 and thereby promoting the nuclear accumulation of the antagonistically acting and transcriptionally repressive isoform STAT1β. Moreover, BAL1 physically interacts with both isoforms of STAT1, STAT1α and STAT1β through its macro domains in an ADP-ribosylation dependent manner. BAL1 directly inhibits together with STAT1β the expression of tumor suppressor and interferon response factor (IRF)-1. Conversely, BAL1 enhances the expression of the proto-oncogenes IRF2 and B-cell CLL/lymphoma (BCL)-6 in DLBCL. Our results show the first time that BAL1 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-53 axes and mediates proliferation, survival and chemo-resistance in DLBCL. As a consequence constitutive IFNγ-STAT1 signaling does not lead to apoptosis but rather to chemo-resistance in DLBCL overexpressing BAL1. Our results suggest that BAL1 may induce an oncogenic switch in STAT1 from a tumor suppressor to an oncogene in high-risk DLBCL.
Collapse
|
29
|
Soldini D, Montagna C, Schüffler P, Martin V, Georgis A, Thiesler T, Curioni-Fontecedro A, Went P, Bosshard G, Dehler S, Mazzuchelli L, Tinguely M. A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome. Ann Oncol 2013; 24:193-201. [DOI: 10.1093/annonc/mds209] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
|
30
|
|
31
|
Fritzsche FR, Ramach C, Soldini D, Caduff R, Tinguely M, Cassoly E, Moch H, Stewart A. Occupational health risks of pathologists--results from a nationwide online questionnaire in Switzerland. BMC Public Health 2012; 12:1054. [PMID: 23216705 PMCID: PMC3538703 DOI: 10.1186/1471-2458-12-1054] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2012] [Accepted: 12/03/2012] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Pathologists are highly trained medical professionals who play an essential part in the diagnosis and therapy planning of malignancies and inflammatory diseases. Their work is associated with potential health hazards including injuries involving infectious human tissue, chemicals which are assumed to be carcinogenic or long periods of microscope and computer work. This study aimed to provide the first comprehensive assessment of the health situation of pathologists in Switzerland. METHODS Pathologists in Switzerland were contacted via the Swiss Society of Pathologists and asked to answer an ethically approved, online anonymous questionnaire comprising 48 questions on occupational health problems, workplace characteristics and health behaviour. RESULTS 163 pathologists participated in the study. Forty percent of pathologists reported musculoskeletal problems in the previous month. The overall prevalence was 76%. Almost 90% of pathologists had visual refraction errors, mainly myopia. 83% of pathologists had experienced occupational injuries, mostly cutting injuries, in their professional career; more than one fifth of participants reported cutting injuries in the last year. However, long lasting injuries and infectious diseases were rare. Depression and burnout affected every eighth pathologist. The prevalence of smoking was substantially below that of the general Swiss population. CONCLUSIONS The results of this study suggest that more care should be taken in technical and personal protective measures, ergonomic workplace optimisation and reduction of work overload and work inefficiencies. Despite the described health risks, Swiss pathologists were optimistic about their future and their working situation. The high rate of ametropia and psychological problems warrants further study.
Collapse
|
32
|
Rozati S, Kerl K, Kempf W, Tinguely M, Zimmermann DR, Dummer R, Cozzio A. Spindle-cell variant of primary cutaneous follicle center lymphoma spreading to the hepatobiliary tree, mimicking Klatskin tumor. J Cutan Pathol 2012; 40:56-60. [DOI: 10.1111/cup.12017] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2011] [Revised: 05/16/2012] [Accepted: 06/03/2012] [Indexed: 11/28/2022]
Affiliation(s)
- Sima Rozati
- Department of Dermatology; University Hospital of Zurich; Zurich; Switzerland
| | - Katrin Kerl
- Department of Dermatology; University Hospital of Zurich; Zurich; Switzerland
| | - Werner Kempf
- Department of Dermatology; University Hospital of Zurich; Zurich; Switzerland
| | - Marianne Tinguely
- Institute of Surgical Pathology; University Hospital of Zurich; Zurich; Switzerland
| | - Dieter R. Zimmermann
- Institute of Surgical Pathology; University Hospital of Zurich; Zurich; Switzerland
| | - Reinhard Dummer
- Department of Dermatology; University Hospital of Zurich; Zurich; Switzerland
| | - Antonio Cozzio
- Department of Dermatology; University Hospital of Zurich; Zurich; Switzerland
| |
Collapse
|
33
|
Wagner C, Schär D, Tinguely M, Kunz I. Persistent fever, neck swelling, and small vessel vasculitis following tonsillectomy in a patient with Behçet's disease: a case report. J Med Case Rep 2012; 6:371. [PMID: 23110825 PMCID: PMC3514192 DOI: 10.1186/1752-1947-6-371] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2012] [Accepted: 09/26/2012] [Indexed: 12/02/2022] Open
Abstract
Introduction Behçet’s disease commonly presents with recurrent oral and genital mucocutaneous ulcerations, uveitis and various skin manifestations. Other clinical symptoms include gastrointestinal ulcerations, arthritis, venous thrombosis, arterial aneurysms and central nervous system affection. Vasculitis underlies most clinical symptoms of Behçet’s disease. Case presentation We report the case of a 62-year-old European Caucasian woman with Behçet’s disease who presented with persistent fever and neck soft-tissue swelling, despite broad antibiotic treatment, two weeks after acute tonsillitis and a tonsillectomy. Diffuse epi- and mesopharyngeal swelling shown on a computed tomography scan of her neck and persistently elevated serum markers of inflammation initially prompted suspicion of an infectious etiology. Magnet resonance imaging of her neck and a neck tissue biopsy finally confirmed small vessel vasculitis involving skin, subcutaneous tissue and muscle. Considering the clinical presentation, past medical history and histological findings, we interpreted our patient’s symptoms as a flare of Behçet’s disease. Immunosuppressive treatment led to rapid clinical improvement. Conclusion A patient with Behçet’s disease developed small vessel vasculitis of the soft tissue of her neck after tonsillitis and a tonsillectomy. Infection and surgery probably triggered a flare of Behçet’s disease.
Collapse
Affiliation(s)
- Claudia Wagner
- University Hospital of Zurich, Clinic of Internal Medicine, Zürich, Switzerland.
| | | | | | | |
Collapse
|
34
|
Tinguely M, Obreschkow D, Kobel P, Dorsaz N, de Bosset A, Farhat M. Energy partition at the collapse of spherical cavitation bubbles. Phys Rev E Stat Nonlin Soft Matter Phys 2012; 86:046315. [PMID: 23214685 DOI: 10.1103/physreve.86.046315] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/01/2012] [Revised: 08/30/2012] [Indexed: 06/01/2023]
Abstract
Spherically collapsing cavitation bubbles produce a shock wave followed by a rebound bubble. Here we present a systematic investigation of the energy partition between the rebound and the shock. Highly spherical cavitation bubbles are produced in microgravity, which suppresses the buoyant pressure gradient that otherwise deteriorates the sphericity of the bubbles. We measure the radius of the rebound bubble and estimate the shock energy as a function of the initial bubble radius (2-5.6mm) and the liquid pressure (10-80kPa). Those measurements uncover a systematic pressure dependence of the energy partition between rebound and shock. We demonstrate that these observations agree with a physical model relying on a first-order approximation of the liquid compressibility and an adiabatic treatment of the noncondensable gas inside the bubble. Using this model we find that the energy partition between rebound and shock is dictated by a single nondimensional parameter ξ=Δpγ6/[p(g0)1/γ(ρc2)1-1/γ], where Δp=p∞ - pv is the driving pressure, p∞ is the static pressure in the liquid, pv is the vapor pressure, pg0 is the pressure of the noncondensable gas at the maximal bubble radius, γ is the adiabatic index of the noncondensable gas, ρ is the liquid density, and c is the speed of sound in the liquid.
Collapse
Affiliation(s)
- M Tinguely
- Laboratoire des Machines Hydrauliques, EPFL, 1007 Lausanne, Switzerland
| | | | | | | | | | | |
Collapse
|
35
|
Kwanhian W, Lenze D, Alles J, Motsch N, Barth S, Döll C, Imig J, Hummel M, Tinguely M, Trivedi P, Lulitanond V, Meister G, Renner C, Grässer FA. MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma. Cancer Med 2012; 1:141-55. [PMID: 23342264 PMCID: PMC3544448 DOI: 10.1002/cam4.29] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2012] [Revised: 08/13/2012] [Accepted: 08/14/2012] [Indexed: 12/13/2022] Open
Abstract
MicroRNAs (miRNAs) are short 18–23 nucleotide long noncoding RNAs that posttranscriptionally regulate gene expression by binding to mRNA. Our previous miRNA profiling of diffuse large B-cell lymphoma (DLBCL) revealed a mutation in the seed sequence of miR-142-3p. Further analysis now showed that miR-142 was mutated in 11 (19.64%) of the 56 DLBCL cases. Of these, one case had a mutation in both alleles, with the remainder being heterozygous. Four mutations were found in the mature miR-142-5p, four in the mature miR-142-3p, and three mutations affected the miR-142 precursor. Two mutations in the seed sequence redirected miR-142-3p to the mRNA of the transcriptional repressor ZEB2 and one of them also targeted the ZEB1 mRNA. However, the other mutations in the mature miR-142-3p did not influence either the ZEB1 or ZEB2 3′ untranslated region (3′ UTR). On the other hand, the mutations affecting the seed sequence of miR-142-3p resulted in a loss of responsiveness in the 3′ UTR of the known miR-142-3p targets RAC1 and ADCY9. In contrast to the mouse p300 gene, the human p300 gene was not found to be a target for miR-142-5p. In one case with a mutation of the precursor, we observed aberrant processing of the miR-142-5p. Our data suggest that the mutations in miR-142 probably lead to a loss rather than a gain of function. This is the first report describing mutations of a miRNA gene in a large percentage of a distinct lymphoma subtype.
Collapse
Affiliation(s)
- Wiyada Kwanhian
- Institute of Virology, Saarland University Medical School 66421, Homburg, Germany; Department of Microbiology, Faculty of Medicine, Khon Kaen University 40002, Khon Kaen, Thailand
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Ghigna MR, Reineke T, Rincé P, Schüffler P, El Mchichi B, Fabre M, Jacquemin E, Durrbach A, Samuel D, Joab I, Guettier C, Lucioni M, Paulli M, Tinguely M, Raphael M. Epstein-Barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders. Pathobiology 2012; 80:53-9. [PMID: 22868923 DOI: 10.1159/000339722] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2012] [Accepted: 05/25/2012] [Indexed: 11/19/2022] Open
Abstract
Posttransplant lymphoproliferative disorders (PTLD) represent a spectrum of lymphoid diseases complicating the clinical course of transplant recipients. Most PTLD are Epstein-Barr virus (EBV) associated with viral latency type III. Several in vitro studies have revealed an interaction between EBV latency proteins and molecules of the apoptosis pathway. Data on human PTLD regarding an association between Bcl-2 family proteins and EBV are scarce. We analyzed 60 primary PTLD for expression of 8 anti- (Bcl-2, Bcl-XL, and Mcl-1) and proapoptotic proteins (Bak and Bax), the so-called BH3-only proteins (Bad, Bid, Bim, and Puma), as well as the apoptosis effector cleaved PARP by immunohistochemistry. Bim and cleaved PARP were both significantly (p = 0.001 and p = 5.251e-6) downregulated in EBV-positive compared to EBV-negative PTLD [Bim: 6/40 (15%), cleaved PARP: 10/43 (23%), vs. Bim: 13/16 (81%), cleaved PARP: 12/17 (71%)]. Additionally, we observed a tendency toward increased Bcl-2 protein expression (p = 0.24) in EBV-positive PTLD. Hence, we provide evidence of a distinct regulation of Bcl-2 family proteins in EBV-positive versus negative PTLD. The low-expression pattern of the proapoptotic proteins Bim and cleaved PARP together with the high-expression pattern of the antiapoptotic protein Bcl-2 by trend in EBV-positive tumor cells suggests disruption of the apoptotic pathway by EBV in PTLD, promoting survival signals in the host cells.
Collapse
Affiliation(s)
- Maria-Rosa Ghigna
- Service d'Anatomie et Cytologie Pathologiques, Hôpital Paul-Brousse, Hôpital Bicêtre, AP-HP, Université Paris-Sud, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Oschlies I, Lisfeld J, Lamant L, Nakazawa A, d'Amore ESG, Hansson U, Hebeda K, Simonitsch-Klupp I, Maldyk J, Müllauer L, Tinguely M, Stücker M, Ledeley MC, Siebert R, Reiter A, Brugières L, Klapper W, Woessmann W. ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. Haematologica 2012; 98:50-6. [PMID: 22773605 DOI: 10.3324/haematol.2012.065664] [Citation(s) in RCA: 77] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Anaplastic large cell lymphomas are peripheral T-cell lymphomas that are characterized by a proliferation of large anaplastic blasts expressing CD30. In children, systemic anaplastic large cell lymphomas often present at advanced clinical stage and harbor translocations involving the anaplastic lymphoma kinase (ALK) gene leading to the expression of chimeric anaplastic lymphoma kinase (ALK)-fusion proteins. Primary cutaneous anaplastic large cell lymphoma is regarded as an ALK-negative variant confined to the skin and is part of the spectrum of primary cutaneous CD30-positive T-cell lymphoproliferative disorders. Thirty-three of 487 pediatric patients registered within the Anaplastic Large Cell Lymphoma-99 trial (1999 to 2006) presented with a skin limited CD30-positive lympho-proliferative disorder. In 23 of the 33 patients, material for international histopathological review was available, and the cases were studied for histopathological, immunophenotypical and clinical features as well as for breaks within the ALK gene. Five of 23 cases and one additional case (identified after closure of the trial) expressed ALK-protein. Complete staging excluded any other organ involvement in all children. Expression of ALK proteins was demonstrated by immunohistochemistry in all cases and the presence of breaks of the ALK gene was genetically confirmed in 5 evaluable cases. The histopathological and clinical picture of these skin-restricted ALK-positive lymphomas was indistinguishable from that of cutaneous anaplastic large cell lymphoma. Five children presented with a single skin lesion that was completely resected in 4 and incompletely resected in one. Three of these patients received no further therapy, 2 additional local radiotherapy, and one chemotherapy. All children remain in complete remission with a median follow up of seven years (range 1-8 years). We present 6 pediatric cases of ALK-positive primary cutaneous anaplastic large cell lymphomas. After thorough exclusion of systemic involvement, therapy confined to local measures seems to be sufficient to induce cure.
Collapse
Affiliation(s)
- Ilske Oschlies
- Department of Pathology, Hematopathology Section and Lymph Node Registry, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Abstract
The role of cytology has so far been underrecognized in the diagnostic process of hematopathological questions. This article presents an algorithm which allows a stepwise work-up of cytology specimens obtained by minimally invasive ultrasound-guided fine needle aspiration in patients with unexplained lymph node swelling. Moreover, it is shown how the selective separation of cytology specimens allows the application of immunophenotypic analysis including flow cytometry and immunohistochemistry as well as molecular analyses, such as fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) strategies. With the integrative procedure presented, cytology offers an excellent cost-effective tool for the diagnostic approach of patients with suspected hematopathological malignancies allowing a high diagnostic accuracy, ideal for initial diagnosis or follow-up.
Collapse
Affiliation(s)
- B Bode
- Institut für Klinische Pathologie, Universtitätsspital Zürich, Schmelzbergstr. 12, 8091, Zürich, Schweiz.
| | | |
Collapse
|
39
|
Mihic-Probst D, Ikenberg K, Tinguely M, Schraml P, Behnke S, Seifert B, Civenni G, Sommer L, Moch H, Dummer R. Tumor cell plasticity and angiogenesis in human melanomas. PLoS One 2012; 7:e33571. [PMID: 22442699 PMCID: PMC3307737 DOI: 10.1371/journal.pone.0033571] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2011] [Accepted: 02/16/2012] [Indexed: 12/20/2022] Open
Abstract
Recent molecular studies provide evidence for a significant transcriptional plasticity of tumor cell subpopulations that facilitate an active contribution to tumor vasculature. This feature is accompanied by morphological changes both in vitro and in vivo. Herein, we investigated the morphological plasticity of tumor cells with special focus on vasculogenic mimicry and neovascularisation in human melanoma and mouse xenografts of human melanoma cell lines. In melanoma xenograft experiments, different vessel markers and green fluorescent protein expression were used to show how melanoma cells contribute to neovascularization. Additionally, we analyzed neovascularization in 49 primary melanomas and 175 melanoma metastases using immunostaining for blood (CD34) and lymphatic (D2-40) vessel-specific markers. We found significantly more lymphatic vessels in primary melanomas than in melanoma metastases (p<0.0001). In contrast to the near absence of lymphatic vessels within metastases, we found extensive blood micro-neovascularization. Blood micro-neovascularization was absent in micro metastases (less than 2 mm). A significant inverse correlation between Glut-1 expression (implying local hypoxia) and the presence of microvessels indicates their functional activity as blood vessels (p<0.0001). We suggest that the hypoxic microenvironment in metastases contributes to a phenotype switch allowing melanoma cells to physically contribute to blood vessel formation.
Collapse
Affiliation(s)
- Daniela Mihic-Probst
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Zuercher E, Butticaz C, Wyniger J, Martinez R, Battegay M, Boffi El Amari E, Dang T, Egger JF, Fehr J, Mueller-Garamvögyi E, Parini A, Schaefer SC, Schoeni-Affolter F, Thurnheer C, Tinguely M, Telenti A, Rothenberger S. Genetic diversity of EBV-encoded LMP1 in the Swiss HIV Cohort Study and implication for NF-Κb activation. PLoS One 2012; 7:e32168. [PMID: 22384168 PMCID: PMC3285206 DOI: 10.1371/journal.pone.0032168] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2011] [Accepted: 01/21/2012] [Indexed: 12/21/2022] Open
Abstract
Epstein-Barr virus (EBV) is associated with several types of cancers including Hodgkin's lymphoma (HL) and nasopharyngeal carcinoma (NPC). EBV-encoded latent membrane protein 1 (LMP1), a multifunctional oncoprotein, is a powerful activator of the transcription factor NF-κB, a property that is essential for EBV-transformed lymphoblastoid cell survival. Previous studies reported LMP1 sequence variations and induction of higher NF-κB activation levels compared to the prototype B95-8 LMP1 by some variants. Here we used biopsies of EBV-associated cancers and blood of individuals included in the Swiss HIV Cohort Study (SHCS) to analyze LMP1 genetic diversity and impact of sequence variations on LMP1-mediated NF-κB activation potential. We found that a number of variants mediate higher NF-κB activation levels when compared to B95-8 LMP1 and mapped three single polymorphisms responsible for this phenotype: F106Y, I124V and F144I. F106Y was present in all LMP1 isolated in this study and its effect was variant dependent, suggesting that it was modulated by other polymorphisms. The two polymorphisms I124V and F144I were present in distinct phylogenetic groups and were linked with other specific polymorphisms nearby, I152L and D150A/L151I, respectively. The two sets of polymorphisms, I124V/I152L and F144I/D150A/L151I, which were markers of increased NF-κB activation in vitro, were not associated with EBV-associated HL in the SHCS. Taken together these results highlighted the importance of single polymorphisms for the modulation of LMP1 signaling activity and demonstrated that several groups of LMP1 variants, through distinct mutational paths, mediated enhanced NF-κB activation levels compared to B95-8 LMP1.
Collapse
Affiliation(s)
- Emilie Zuercher
- Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Christophe Butticaz
- Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Josiane Wyniger
- Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Raquel Martinez
- Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Manuel Battegay
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
| | | | - Thanh Dang
- Infectious Diseases Service, University Hospital and University of Lausanne, Lausanne, Switzerland
| | | | - Jan Fehr
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital and University of Zurich, Zurich, Switzerland
| | | | - Andrea Parini
- Medical Service, Ospedale Regionale, Lugano, Switzerland
| | - Stephan C. Schaefer
- Institute of Pathology, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Franziska Schoeni-Affolter
- Swiss HIV Cohort Study Data Center, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Christine Thurnheer
- Division of Infectious Diseases, University Hospital and University of Bern, Bern, Switzerland
| | - Marianne Tinguely
- Institute of Surgical Pathology, University Hospital and University of Zurich, Zurich, Switzerland
| | - Amalio Telenti
- Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Sylvia Rothenberger
- Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
- * E-mail:
| | | |
Collapse
|
41
|
Petrausch U, Samaras P, Mischo A, Stenner F, Tinguely M, Schäfer N, Studer G, Renner C. [After care in Hodgkin lymphoma]. Praxis (Bern 1994) 2011; 100:1515-1522. [PMID: 22161876 DOI: 10.1024/1661-8157/a000744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
MESH Headings
- Aftercare/methods
- Biopsy
- Combined Modality Therapy
- Early Diagnosis
- Hodgkin Disease/diagnosis
- Hodgkin Disease/pathology
- Hodgkin Disease/therapy
- Humans
- Lymphoma, Large B-Cell, Diffuse/diagnosis
- Lymphoma, Large B-Cell, Diffuse/pathology
- Lymphoma, Large B-Cell, Diffuse/therapy
- Male
- Middle Aged
- Neoplasm Recurrence, Local/diagnosis
- Neoplasm Recurrence, Local/pathology
- Neoplasm Recurrence, Local/therapy
- Neoplasm Staging
- Neoplasms, Second Primary/diagnosis
- Neoplasms, Second Primary/pathology
- Neoplasms, Second Primary/therapy
- Physical Examination
- Positron-Emission Tomography
- Stomach/pathology
- Stomach Neoplasms/diagnosis
- Stomach Neoplasms/pathology
- Stomach Neoplasms/therapy
- Tomography, X-Ray Computed
- Ultrasonography
Collapse
Affiliation(s)
- U Petrausch
- Klinik für Immunologie, Universitätsspital Zürich
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Obreschkow D, Tinguely M, Dorsaz N, Kobel P, de Bosset A, Farhat M. Universal scaling law for jets of collapsing bubbles. Phys Rev Lett 2011; 107:204501. [PMID: 22181734 DOI: 10.1103/physrevlett.107.204501] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2011] [Indexed: 05/31/2023]
Abstract
Cavitation bubbles collapsing and rebounding in a pressure gradient ∇p form a "microjet" enveloped by a "vapor jet." This Letter presents unprecedented observations of the vapor jets formed in a uniform gravity-induced ∇p, modulated aboard parabolic flights. The data uncover that the normalized jet volume is independent of the liquid density and viscosity and proportional to ζ ≡ |∇p|R(0)/Δp, where R(0) the maximal bubble radius and Δp is the driving pressure. A derivation inspired by "Kelvin-Blake" considerations confirms this law and reveals its negligible dependence of surface tension. We further conjecture that the jet only pierces the bubble boundary if ζ ≳ 4 × 10(-4).
Collapse
Affiliation(s)
- D Obreschkow
- Laboratoire des Machines Hydrauliques, EPFL, Lausanne, Switzerland
| | | | | | | | | | | |
Collapse
|
43
|
Matter MS, Hilmenyuk T, Claus C, Marone R, Schürch C, Tinguely M, Terracciano L, Luther SA, Ochsenbein AF. Destruction of lymphoid organ architecture and hepatitis caused by CD4+ T cells. PLoS One 2011; 6:e24772. [PMID: 21966366 PMCID: PMC3179489 DOI: 10.1371/journal.pone.0024772] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2011] [Accepted: 08/17/2011] [Indexed: 11/19/2022] Open
Abstract
Immune responses have the important function of host defense and protection against pathogens. However, the immune response also causes inflammation and host tissue injury, termed immunopathology. For example, hepatitis B and C virus infection in humans cause immunopathological sequel with destruction of liver cells by the host's own immune response. Similarly, after infection with lymphocytic choriomeningitis virus (LCMV) in mice, the adaptive immune response causes liver cell damage, choriomeningitis and destruction of lymphoid organ architecture. The immunopathological sequel during LCMV infection has been attributed to cytotoxic CD8(+) T cells. However, we now show that during LCMV infection CD4(+) T cells selectively induced the destruction of splenic marginal zone and caused liver cell damage with elevated serum alanin-transferase (ALT) levels. The destruction of the splenic marginal zone by CD4(+) T cells included the reduction of marginal zone B cells, marginal zone macrophages and marginal zone metallophilic macrophages. Functionally, this resulted in an impaired production of neutralizing antibodies against LCMV. Furthermore, CD4(+) T cells reduced B cells with an IgM(high)IgD(low) phenotype (transitional stage 1 and 2, marginal zone B cells), whereas other B cell subtypes such as follicular type 1 and 2 and germinal center/memory B cells were not affected. Adoptive transfer of CD4(+) T cells lacking different important effector cytokines and cytolytic pathways such as IFNγ, TNFα, perforin and Fas-FasL interaction did reveal that these cytolytic pathways are redundant in the induction of immunopathological sequel in spleen. In conclusion, our results define an important role of CD4(+) T cells in the induction of immunopathology in liver and spleen. This includes the CD4(+) T cell mediated destruction of the splenic marginal zone with consecutively impaired protective neutralizing antibody responses.
Collapse
MESH Headings
- Adoptive Transfer
- Animals
- Antibodies, Neutralizing/immunology
- Antibodies, Neutralizing/metabolism
- Antibodies, Viral/immunology
- Antibodies, Viral/metabolism
- B-Lymphocytes/immunology
- B-Lymphocytes/metabolism
- CD4-Positive T-Lymphocytes/immunology
- CD4-Positive T-Lymphocytes/metabolism
- CD8-Positive T-Lymphocytes/immunology
- CD8-Positive T-Lymphocytes/metabolism
- Chemokines/genetics
- Chemokines/immunology
- Chemokines/metabolism
- Fas Ligand Protein/deficiency
- Fas Ligand Protein/genetics
- Fas Ligand Protein/immunology
- Flow Cytometry
- Hepatitis, Viral, Animal/immunology
- Hepatitis, Viral, Animal/metabolism
- Hepatitis, Viral, Animal/virology
- Interferon-gamma/deficiency
- Interferon-gamma/genetics
- Interferon-gamma/immunology
- Lymphocytic Choriomeningitis/immunology
- Lymphocytic Choriomeningitis/metabolism
- Lymphocytic choriomeningitis virus/immunology
- Lymphoid Tissue/immunology
- Lymphoid Tissue/metabolism
- Lymphoid Tissue/virology
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Mice, Transgenic
- Microscopy, Fluorescence
- Perforin/deficiency
- Perforin/genetics
- Perforin/immunology
- Reverse Transcriptase Polymerase Chain Reaction
- Spleen/immunology
- Spleen/metabolism
- Spleen/virology
- Time Factors
- Tumor Necrosis Factor-alpha/deficiency
- Tumor Necrosis Factor-alpha/genetics
- Tumor Necrosis Factor-alpha/immunology
Collapse
Affiliation(s)
- Matthias S Matter
- Tumor Immunology, Department of Clinical Research, University of Bern, Bern, Switzerland.
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Imig J, Motsch N, Zhu JY, Barth S, Okoniewski M, Reineke T, Tinguely M, Faggioni A, Trivedi P, Meister G, Renner C, Grässer FA. microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res 2010; 39:1880-93. [PMID: 21062812 PMCID: PMC3061055 DOI: 10.1093/nar/gkq1043] [Citation(s) in RCA: 121] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The Epstein–Barr virus (EBV) is an oncogenic human Herpes virus found in ∼15% of diffuse large B-cell lymphoma (DLBCL). EBV encodes miRNAs and induces changes in the cellular miRNA profile of infected cells. MiRNAs are small, non-coding RNAs of ∼19–26 nt which suppress protein synthesis by inducing translational arrest or mRNA degradation. Here, we report a comprehensive miRNA-profiling study and show that hsa-miR-424, -223, -199a-3p, -199a-5p, -27b, -378, -26b, -23a, -23b were upregulated and hsa-miR-155, -20b, -221, -151-3p, -222, -29b/c, -106a were downregulated more than 2-fold due to EBV-infection of DLBCL. All known EBV miRNAs with the exception of the BHRF1 cluster as well as EBV-miR-BART15 and -20 were present. A computational analysis indicated potential targets such as c-MYB, LATS2, c-SKI and SIAH1. We show that c-MYB is targeted by miR-155 and miR-424, that the tumor suppressor SIAH1 is targeted by miR-424, and that c-SKI is potentially regulated by miR-155. Downregulation of SIAH1 protein in DLBCL was demonstrated by immunohistochemistry. The inhibition of SIAH1 is in line with the notion that EBV impedes various pro-apoptotic pathways during tumorigenesis. The down-modulation of the oncogenic c-MYB protein, although counter-intuitive, might be explained by its tight regulation in developmental processes.
Collapse
Affiliation(s)
- Jochen Imig
- Institute of Microbiology and Hygiene, Department of Virology, University Hospital of Saarland University, Homburg/Saar
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Schmid S, Tinguely M, Cione P, Moch H, Bode B. Flow cytometry as an accurate tool to complement fine needle aspiration cytology in the diagnosis of low grade malignant lymphomas. Cytopathology 2010; 22:397-406. [DOI: 10.1111/j.1365-2303.2010.00801.x] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
46
|
Albinger-Hegyi A, Stoeckli SJ, Schmid S, Storz M, Iotzova G, Probst-Hensch NM, Rehrauer H, Tinguely M, Moch H, Hegyi I. Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). Int J Cancer 2010; 126:2653-62. [PMID: 19816945 DOI: 10.1002/ijc.24948] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Proteins of the lysyl oxidase (LOX) family are important modulators of the extracellular matrix. However, they have an important role in the tumour development as well as in tumour progression. To evaluate the diagnostic and prognostic value of the LOX protein in oral and oropharyngeal squamous cell carcinoma (OSCC) we performed QRT-PCR and immunohistochemical analysis on two tissue microarrays (622 tissue samples in total). Significantly higher LOX expression was detected in high grade dysplastic oral mucosa as well as in OSCC when compared to normal oral mucosa (P < 0.001). High LOX expression was correlated with clinical TNM stage (P = 0.020), lymph node metastases for the entire cohort (P < 0.001), as well as in the subgroup of small primary tumours (T1/T2, P < 0.001). Moreover, high LOX expression was correlated with poor overall survival (P = 0.004) and disease specific survival (P = 0.037). In a multivariate analysis, high LOX expression was an independent prognostic factor, predicting unfavourable overall survival. In summary, LOX expression is an independent prognostic biomarker and a predictor of lymph node metastasis in OSCC. Moreover, LOX overexpression may be an early phenomenon in the pathogenesis of OSCC and thus an attractive novel target for chemopreventive and therapeutic strategies.
Collapse
Affiliation(s)
- Andrea Albinger-Hegyi
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Dorner M, Brandt S, Tinguely M, Zucol F, Bourquin JP, Zauner L, Berger C, Bernasconi M, Speck RF, Nadal D. Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology 2010; 128:573-9. [PMID: 19950420 DOI: 10.1111/j.1365-2567.2009.03143.x] [Citation(s) in RCA: 79] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Toll-like receptors (TLRs) are key receptors of the innate immune system and show cell subset-specific expression. We investigated the messenger RNA (mRNA) expression of TLR genes in human haematopoietic stem cells (HSC), in naïve B cells, in memory B cells, in plasma cells from palatine tonsils and in plasma cells from peripheral blood. HSC and plasma cells showed unrestricted expression of TLR1-TLR9, in contrast to B cells which lacked TLR3, TLR4 and TLR8 but expressed mRNA of all other TLRs. We demonstrated, for the first time, that TLR triggering of terminally differentiated plasma cells augments immunoglobulin production. Thus, boosting the immediate antibody response by plasma cells upon pathogen recognition may point to a novel role of TLRs.
Collapse
Affiliation(s)
- Marcus Dorner
- Division of Infectious Diseases and Hospital Epidemiology, Children's Hospital of Zurich, Zurich, Switzerland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Broglie MA, Tinguely M, Holzman D. How to diagnose sinus fungus balls in the paranasal sinus? An analysis of an institution's cases from January 1999 to December 2006. Rhinology 2010; 47:379-84. [PMID: 19936362 DOI: 10.4193/rhin09.026] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The diagnosis of a sinus fungus ball (SFB) is often not clear despite well-defined diagnostic criteria. OBJECTIVE To study the radiological, intraoperative and histological diagnostic accuracy in comparison to results from mycological and histological analysis. METHODS Systematic review of 724 files from patients treated for chronic rhinosinusitis from 1999 - 2006 at our institution. RESULTS The sensitivity, specificity, positive and negative predictive value (PPV, NPV) of pre- operative CT imaging was 83%, 94%, 56% and 98% respectively, whereas, based on intra- operative findings, it was 98%, 93%, 57% and 100%. CONCLUSIONS A high number of misdiagnoses was found possibly due to sampling error. A severe inflammatory reaction of the surrounding tissue was found more often in SFB than in controls in our study and this we suggest could be an additional sign for fungal infection. Fungal cultures did not contribute to a correct diagnosis.
Collapse
Affiliation(s)
- M A Broglie
- Department of Otorhinolaryngology - Head and Neck Surgery, University Hospital of Zurich, Zürich, Switzerland.
| | | | | |
Collapse
|
49
|
Leuenberger M, Frigerio S, Wild PJ, Noetzli F, Korol D, Zimmermann DR, Gengler C, Probst-Hensch NM, Moch H, Tinguely M. AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations. Mod Pathol 2010; 23:177-86. [PMID: 19898425 DOI: 10.1038/modpathol.2009.156] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The biological behavior of chronic lymphocytic leukemia and small lymphocytic lymphoma is unpredictable. Nonetheless, non-mutated IgV(H) gene rearrangement, ATM (11q22-23) and p53 (17p13) deletion are recognized as unfavorable prognosticators in chronic lymphocytic leukemia. The mRNA expression of activation-induced cytidine deaminase (AID), an enzyme indispensable for somatic hypermutation processes, was claimed to be predictive of non-mutated chronic lymphocytic leukemia cells in blood. Here, we evaluated AID protein expression compared with known molecular and immunohistochemical prognostic indicators in 71 chronic lymphocytic leukemia/small lymphocytic lymphoma patients using a tissue microarray approach. We found AID heterogeneously expressed in tumor cells as shown by colocalization analysis for CD5 and CD23. Ki-67 positive paraimmunoblasts of the proliferation centers displayed the highest expression. This observation is reflected by a significant association of AID positivity with a high proliferation rate (P=0.012). ATM deletion was detected in 10% (6/63) of patients and p53 deletion in 19% (13/67) of patients. Moreover, both ATM (P=0.002) and p53 deletion (P=0.004) were significantly associated with AID. IgV(H) gene mutation was seen in 45% (27/60) of patients. Twenty-five percent (17/69) of patients with AID-positive chronic lymphocytic leukemia/small lymphocytic lymphoma displayed a shorter survival than AID-negative chronic lymphocytic leukemia/small lymphocytic lymphoma patients (61 vs 130 months, P=0.001). Although there was a trend, we could not show an association with the IgV(H) gene mutation status. Taken together, our study shows that AID expression is an indicator of an unfavorable prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma patients, although it is not a surrogate marker for the IgV(H) status. Furthermore, the microenvironment of proliferation centers seems to influence AID regulation and might be an initiating factor in its transformation.
Collapse
Affiliation(s)
- Mona Leuenberger
- Department of Pathology, Institute of Surgical Pathology, University Hospital, CH-8091Zurich, Switzerland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Affiliation(s)
- M A Broglie
- Klinik für Ohren-, Nasen-, Hals- und Gesichtschirurgie, Universitätsspital Zürich, Frauenklinikstrasse 24, 8091, Zürich, Schweiz.
| | | | | | | |
Collapse
|